Brief: Cel-Sci’S Announces Phase 3 Study Results
17/10/2022 14:37
Oct 17 (Reuters) - CEL-SCI Corp CVM.A :
* CEL-SCI’S MULTIKINE REDUCED 5-YEAR DEATH RATE FROM 54% TO
22% IN
PHASE 3 STUDY PATIENTS WHO WERE EARLY TUMOR RESPONDERS PRIOR TO
ANY STANDARD OF CARE TREATMENT
Source text for Eikon: ID:nBw8hFlYa
Further company coverage: CVM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CEL-SCI
See all newsBrief: CEL-SCI Announces Closing Of Offering
Brief: Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing
Brief: Cel-Sci Corporation Announces Pricing Of Public Offering
Brief: CEL-SCI Enters Strategic Agreement With Amarox For The Registration, Commercialization, And Distribution Of Multikine In Saudi Arabia
Drug developer CEL-SCI dives on deep-discounted equity raise